Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Philip James Wealth Mangement LLC

Key Points

• Philip James Wealth Management LLC increased its stake in Jazz Pharmaceuticals by 42% during Q2, owning 15,797 shares worth approximately $1.68 million.
• Jazz Pharmaceuticals has received multiple rating updates from analysts, with a buy rating and a price target range from $151 to $202 from various institutions.
• Institutional investors hold a significant 89.14% of Jazz Pharmaceuticals' stock, reflecting strong interest in the company among larger financial entities.

Philip James Wealth Mangement LLC grew its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 42.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,797 shares of the specialty pharmaceutical company's stock after purchasing an additional 4,675 shares during the quarter. Philip James Wealth Mangement LLC's holdings in Jazz Pharmaceuticals were worth $1,676,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hurley Capital LLC acquired a new stake in Jazz Pharmaceuticals during the first quarter worth about $25,000. Parallel Advisors LLC raised its stake in Jazz Pharmaceuticals by 85.6% during the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock worth $32,000 after acquiring an additional 119 shares during the period. Picton Mahoney Asset Management raised its stake in Jazz Pharmaceuticals by 2,445.5% during the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock worth $34,000 after acquiring an additional 269 shares during the period. Spire Wealth Management raised its stake in Jazz Pharmaceuticals by 137.6% during the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock worth $35,000 after acquiring an additional 161 shares during the period. Finally, SVB Wealth LLC acquired a new stake in Jazz Pharmaceuticals during the first quarter worth about $36,000. Institutional investors and hedge funds own 89.14% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a "buy" rating and a $152.00 price objective on the stock. Zacks Research upgraded shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Royal Bank Of Canada lifted their price target on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an "outperform" rating in a report on Thursday, August 28th. Morgan Stanley boosted their price objective on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 24th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Fourteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $178.93.

Insiders Place Their Bets

In related news, Director Bruce C. Cozadd sold 6,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the sale, the director directly owned 429,973 shares in the company, valued at approximately $55,303,127.26. This trade represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Trading Up 3.9%

Jazz Pharmaceuticals stock opened at $136.90 on Thursday. The firm has a 50 day simple moving average of $122.95 and a 200-day simple moving average of $115.86. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The stock has a market capitalization of $8.30 billion, a PE ratio of -20.34, a price-to-earnings-growth ratio of 8.17 and a beta of 0.28. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company's revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business earned $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, equities research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.